LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

A.M. Arance Fernandez, Steven O’Day, Luis de la Cruz‐Merino, Teresa M. Petrella, R. Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Iván Márquez‐Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, A. David Smith, K. Chen, Scott J. Diede, Clemens Krepler, Georgina V. Long